Inclusion Criteria:

- Provision of written informed consent prior to any study related procedures.

- postmenopausal or ovariectomised female patient over 18 years of age.

- histologically confirmed diagnosis of ER positive endometrial carcinoma in the
primary tumour or metastatic disease

- patient has received one line of chemotherapy prior to enrolment in the adjuvant or
in the metastatic setting (including chemoradiotherapy) and progressed after this
line of chemotherapy

- patient has at least one measurable disease site (RECIST criteria version 1.1)

Exclusion Criteria:

- patient has received hormone therapy for endometrial cancer in the adjuvant or
metastatic setting

- patient has received more than one line of chemotherapy in the adjuvant or metastatic
setting

- patient was treated with any other investigational agent within the 3 weeks before
study entry.

- patient has ongoing cardiac dysrhythmias grade ≥2, atrial fibrillation of any grade
(NCI CTCAE) or QTcF interval >460 msec.